Jupiter Neurosciences, Inc. Common Stock (JUNS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jupiter Neurosciences, Inc. Common Stock (JUNS) has a cash flow conversion efficiency ratio of 6.271x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.29 Million) by net assets ($-365.97K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Jupiter Neurosciences, Inc. Common Stock worth for the company's overall valuation and market capitalisation.
Jupiter Neurosciences, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Jupiter Neurosciences, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Jupiter Neurosciences, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jupiter Neurosciences, Inc. Common Stock ranked by their cash flow conversion efficiency. Explore how high is Jupiter Neurosciences, Inc. Common Stock's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Datadot Technology Ltd
AU:DDT
|
-0.008x |
|
First Helium Inc
V:HELI
|
0.009x |
|
Rincon Resources Ltd
AU:RCR
|
-0.029x |
|
StableX Technologies, Inc.
NASDAQ:SBLX
|
-0.139x |
|
Keyang Electric Machinery Co Ltd
KO:012205
|
-0.186x |
|
Zenvia Inc
NASDAQ:ZENV
|
-0.034x |
|
Wellnex Life Ltd
AU:WNX
|
0.154x |
|
Axiom Properties Ltd
AU:AXI
|
-0.145x |
Annual Cash Flow Conversion Efficiency for Jupiter Neurosciences, Inc. Common Stock (2019–2025)
The table below shows the annual cash flow conversion efficiency of Jupiter Neurosciences, Inc. Common Stock from 2019 to 2025. View JUNS stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-1.83 Million | $-5.41 Million | 2.955x | +415.26% |
| 2024-12-31 | $4.17 Million | $-3.91 Million | -0.937x | -1230.76% |
| 2023-12-31 | $-5.80 Million | $-480.95K | 0.083x | -52.56% |
| 2022-12-31 | $-7.14 Million | $-1.25 Million | 0.175x | -47.85% |
| 2021-12-31 | $-5.18 Million | $-1.74 Million | 0.335x | +388.09% |
| 2020-12-31 | $-3.71 Million | $-254.78K | 0.069x | +140.91% |
| 2019-12-31 | $-5.02 Million | $-142.95K | 0.028x | -- |
About Jupiter Neurosciences, Inc. Common Stock
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinic… Read more